Nicotinamide Riboside: A Promising Treatment for Type 1 Cardiorenal Syndrome in Myocardial Infarction‐Induced Acute Kidney Injury by Upregulating Nicotinamide Phosphoribosyltransferase‐Mediated Nicotinamide Dinucleotide Levels
Our findings indicate that NR could potentially be a promising therapy for acute kidney injury following an early stage of MI.
Authors
- Cynthia Tannous
- Reine Diab
- Iman Momken (ORCID: https://orcid.org/0000-0003-2562-252X)
- Rana Ghali
- Solène Emmanuelle Boitard (ORCID: https://orcid.org/0000-0002-2979-4217)
- Fouad A. Zouein (ORCID: https://orcid.org/0000-0003-4451-804X)
- George W. Booz (ORCID: https://orcid.org/0000-0003-1478-9615)
- Nada J. Habeichi (ORCID: https://orcid.org/0000-0003-2636-0242)
- Ghadir Amin (ORCID: https://orcid.org/0000-0002-0570-7254)
- Mathias Mericskay (ORCID: https://orcid.org/0000-0002-6779-092X)
Institutions
- Inserm (FR)
- Université Paris-Saclay (FR)
- University of Mississippi Medical Center (US)
- American University of Beirut Medical Center (LB)
- Laboratory Signaling and Cardiovascular Pathophysiology (FR)
- American University of Beirut (LB)
Publication Details
- Journal
- Journal of the American Heart Association
- Published
- 2025-02-26
- DOI
- https://doi.org/10.1161/jaha.124.038603
- Citations
- 4
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 4.18